The strategic benefits of having a $1B Pharma taking over the costs associated with bringing B-UP/UPS through clinical trials and to market are huge. The benefits of product validation, milestone payments, royalty payments and any upfront payments are important but are secondary to the long term shareholder value of getting Brilacidin to market with multiple instances. The overall IBD market is a gold mine for big pharma and getting a drug through FDA and international trials for UP/UPS opens the door to advance into the lucrative Crohn’s and Colitis markets that are in desperate need for Brilacidin. Alfasigma will have the first right of refusal for these instances but IPIX will be in a powerful negotiating position as other major pharmas will surely have interest. The recent agreement with BDD will accelerate this next major initiative.
I still believe that the first instance of Brilacidin that will be commercially approved will be for OM. I believe Leo will have a separate B-OM partnership deal done shortly and a B-OM Phase 3 will hit the ground running. Having Brilacidin approved for B-OM, multiple IBD instances and possibly dermatitis and other instances in the future will establish IPIX as a royalty based biotech with several streams of revenue from several business partners. As each of these partnerships take place they serve 2 major purposes. First and most obvious is that they create shareholder long term value in the form of royalty payments. Secondly, they off-load and free up IPIX resources to allow IPIX to focus on the next instance or platform. The Kevetrin platform will get increased resources as each Brilacidin instance gets offloaded to IPIX business partners who will take the science and run with it to get it to market. As investors we have ownership of a company that is evolving into the Regeneron model and are invested at the early stages of take-off. As IPIX management continues to execute it will be gradually reflected in IPIX share price while the criminal NSS element gradually lose control of share price compression. Congratulations to Leo on the first of many major milestones in creating this royalty model which will bring great wealth to IPIX shareholders and to serve many people in need of IPIX science.
I still believe that the first instance of Brilacidin that will be commercially approved will be for OM. I believe Leo will have a separate B-OM partnership deal done shortly and a B-OM Phase 3 will hit the ground running. Having Brilacidin approved for B-OM, multiple IBD instances and possibly dermatitis and other instances in the future will establish IPIX as a royalty based biotech with several streams of revenue from several business partners. As each of these partnerships take place they serve 2 major purposes. First and most obvious is that they create shareholder long term value in the form of royalty payments. Secondly, they off-load and free up IPIX resources to allow IPIX to focus on the next instance or platform. The Kevetrin platform will get increased resources as each Brilacidin instance gets offloaded to IPIX business partners who will take the science and run with it to get it to market. As investors we have ownership of a company that is evolving into the Regeneron model and are invested at the early stages of take-off. As IPIX management continues to execute it will be gradually reflected in IPIX share price while the criminal NSS element gradually lose control of share price compression. Congratulations to Leo on the first of many major milestones in creating this royalty model which will bring great wealth to IPIX shareholders and to serve many people in need of IPIX science.
14
